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The potential health beneﬁts of soy, and the
soy isoﬂavones in particular, are widely pub-
licized. Although soy and soy isoflavones
exhibit both risks and beneﬁts (1,2), in this
article we focus on the thyroid toxicity of
genistein. Genistein is the major isoflavone
synthesized by the soybean; genistein pos-
sesses both estrogenic and goitrogenic activi-
ties. The claimed benefits of genistein are
being examined in numerous experimental,
epidemiologic, and clinical studies investi-
gating breast and prostate cancer chemopre-
vention, relief of postmenopausal symptoms,
and prevention or slowing of osteoporosis.
Here, we ﬁrst present a brief summary of the
estrogenic activity and toxicity of genistein
and then explore the potential for thyroid
toxicity of these chemicals, both from a his-
torical perspective and from data reported
from recent investigations on the mecha-
nisms of potential toxicity. We also integrate
research results on isoﬂavone thyroid effects
in a manner useful for predicting and identi-
fying potential risks from soy consumption
in various human populations.
Soy and Isoﬂavone Estrogenic
Activity
Phytoestrogens comprise a class of several
different chemicals produced by a variety of
plants (2). Of these, the soy isoflavones
(particularly genistein) are of greatest interest
because of the widespread human con-
sumption of soy, due largely in Western
countries to extensive advertising by the soy
industry for potential human health bene-
ﬁts. However, despite the widespread belief
that soy consumption is safe, soy
isoflavones administered during develop-
ment can cause several forms of estrogen
toxicity in experimental animals.
As part of a large project to develop a
battery of predictive computational models,
we recently assayed 230 chemicals for binding
to the estrogen receptor (ER) (3). Of these,
46 were phytoestrogens from six different
chemical structure classes. Of the nine
isoﬂavones, seven bound the ER with measur-
able afﬁnity, ranging from a relative binding
afﬁnity (RBA) of 0.45 for genistein to 0.0013
for formononetin, with the RBA for estradiol
being 100. Equol, a metabolite of the phyto-
estrogen daidzein, had an RBA for ER that
was 33% that of genistein (4). When exam-
ined in a battery of rat in vivo assays devel-
oped to assess estrogen activity and toxicity
during postnatal development, equol
increased uterine weight. Also, equol treat-
ment on postnatal days (PNDs) 1–5 inhibited
uterine weight gain on PNDs 20 and 25, as
did coumestrol and diethylstilbestrol (DES)
(4). After PND 10–14 treatment, equol, like
coumestrol and DES, inhibited the develop-
ment of uterine glands. This was a frank toxic
response because the entire uterine tissue
compartment was mostly absent. Recently,
genistein was found to cause uterine adeno-
carcinoma in adult mice, following neonatal
treatment (5). Because earlier DES studies
showed the same effect, equipotent doses of
genistein and DES (the positive control) were
chosen based on uterotrophic activity. The
tumor incidence was statistically the same in
both the DES and genistein groups. This
ﬁnding strongly suggests that the estrogenic
activity per se, and not the chemical structure,
is responsible for this malignant outcome.
When assessed in women in a controlled
trial, a dose of 30 g soy ﬂour/day had frank
estrogenic effects, including lengthening of
the menstrual cycle (6). Infants on soy
infant formula receive a dose of phytoestro-
gens that is 5-fold higher than the dose
causing estrogenic effects in women (7).
This level of soy isoflavone exposure to
approximately 20% of American infants
should be of concern, but no robust studies
in infants have been conducted.
The evidence outlined here is sufficient
to conclude that genistein and equol bind
to the ER, are estrogenic in vivo, and are
estrogenic developmental toxicants; that
genistein is an estrogenic carcinogen in
rodents; and that such exposures may be
relevant to humans.
Goitrogenic Activity of Soy
Isoﬂavones 
Literature Review
It is well described but little known that the
soybean and goiter have long been associated
in animals and humans. Rodents are useful
risk assessment models for thyroid toxicants,
despite signiﬁcant differences between rodent
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Soy is known to produce estrogenic isoﬂavones. Here, we brieﬂy review the evidence for binding
of isoflavones to the estrogen receptor, in vivo estrogenicity and developmental toxicity, and
estrogen developmental carcinogenesis in rats. Genistein, the major soy isoflavone, also has a
frank estrogenic effect in women. We then focus on evidence from animal and human studies
suggesting a link between soy consumption and goiter, an activity independent of estrogenicity.
Iodine deﬁciency greatly increases soy antithyroid effects, whereas iodine supplementation is pro-
tective. Thus, soy effects on the thyroid involve the critical relationship between iodine status and
thyroid function. In rats consuming genistein-fortiﬁed diets, genistein was measured in the thy-
roid at levels that produced dose-dependent and signiﬁcant inactivation of rat and human thyroid
peroxidase (TPO) in vitro. Furthermore, rat TPO activity was dose-dependently reduced by up to
80%. Although these effects are clear and reproducible, other measures of thyroid function
in vivo (serum levels of triiodothyronine, thyroxine, and thyroid-stimulating hormone; thyroid
weight; and thyroid histopathology) were all normal. Additional factors appear necessary for soy
to cause overt thyroid toxicity. These clearly include iodine deﬁciency but may also include addi-
tional soy components, other defects of hormone synthesis, or additional goitrogenic dietary fac-
tors. Although safety testing of natural products, including soy products, is not required, the
possibility that widely consumed soy products may cause harm in the human population via
either or both estrogenic and goitrogenic activities is of concern. Rigorous, high-quality experi-
mental and human research into soy toxicity is the best way to address these concerns. Similar
studies in wildlife populations are also appropriate. Key words: estrogen toxicity, estrogenicity,
genistein, isoflavones, mass spectrometry, soy, thyroid peroxidase, thyroid toxicity. Environ
Health Perspect 110(suppl 3):349–353 (2002).
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and human thyroid physiology (8). In rats the
goitrogenic activity of soy and its inhibition by
dietary iodide supplementation have been
defined (9–13). The negative interaction of
low dietary iodine and soy is demonstrated by
the ﬁnding of Kimura et al. that thyroid carci-
noma appeared in rats fed an iodine-deﬁcient
diet consisting of 30% defatted soy (14). In
humans, goiter has been seen in infants fed soy
formula; this is usually reversed by changing to
cow milk or iodine-supplemented diets
(15–22). After the 1960s, manufacturers
reportedly began adding iodine to formulas to
mitigate thyroid effects. Fort et al. (23) con-
ducted a retrospective epidemiologic study on
teenage children diagnosed with autoimmune
thyroid diseases (Hashimoto’s thyroiditis or
Graves’ disease). Those consuming soy for-
mula as infants had twice the prevalence of
autoimmune disease (18 of 59, 31%) of
healthy siblings (9 of 76, 12%) or controls (7
of 54, 13%). Goiter and high normal thyroid-
stimulating hormone (TSH) levels in healthy
iodine-sufﬁcient adults occurred as early as 1
month (n = 37) after commencing a diet that
included 30 g of pickled soybeans per day
(24). Although it was not measured, dietary
iodine content may have been insufﬁcient to
protect against the antithyroid effect of soy.
Furthermore, no changes in serum thyroid
hormone [triiodothyronine (T3) and thyrox-
ine (T4)] levels were found. After 1 month off
the soy diet, TSH decreased to the pretreat-
ment levels and goiters were diminished in
size. Lowered T3 levels were seen in 14 pre-
menopausal but not in 18 postmenopausal
women on a soy diet (up to 2 mg total of soy
isoﬂavones per kilogram body weight per day)
for about 3 months (25). Interestingly, in
another study, as little as 1 month of soy sup-
plementation decreased T3/T4 levels during
the luteal phase of the menstrual cycle, but lev-
els increased during the follicular phase (26).
Biosynthesis of Thyroid Hormones
and Inhibition by Antithyroid
Chemicals
Thyroid peroxidase (TPO) is found in the
apical membrane of thyroid follicular cells.
TPO, a heme-containing enzyme, catalyzes
both reactions required for thyroid hormone
synthesis (see Scheme 1). The first step is
iodination of thyroglobulin tyrosyl residues,
followed by oxidative coupling to yield T4 and
T3. Inhibition of porcine TPO activity is a
mechanism common to many classes of syn-
thetic antithyroid compounds (27–31) and
naturally occurring flavonoids (32,33).
Lactoperoxidase (LPO) is often used as a
model for TPO, based on many shared struc-
tural and functional properties. For this reason
investigations were started on soy isoﬂavone
inhibition of both porcine TPO and LPO
activity. Genistein and daidzein were found to
be the chemicals in soy that inhibited both
TPO-catalyzed iodination and coupling
(33,34). The nature of the inhibition of enzy-
matic activity under various conditions is quite
interesting, if not startling. First, absent iodide,
genistein and daidzein act as suicide substrates
for TPO and LPO by covalently binding to
the active site. This was shown by the irre-
versible loss of both iodinating and coupling
activities and concomitant changes in the
ultraviolet-visible spectrum of the enzyme.
Second, with adequate iodide, genistein and
daidzein are alternate substrates; products are
mono-, di-, and triiodoisoﬂavones.
Scheme 2 proposes mechanisms by which
genistein can intercept reactive enzyme inter-
mediates involved in the iodination and cou-
pling reactions required for T4 synthesis.
Mechanisms include reaction of compound I
with isoﬂavones that could produce a reactive
isoﬂavone radical at the active site, along with
a radical form of compound II, which could
combine to form inactivated enzyme presum-
ably through covalent modiﬁcation of active
site amino acid residues. Consistent with this
hypothesis are the covalent binding of
approximately 3 mol of radiolabeled genis-
tein per 1 mol of inactivated LPO; the
unchanged heme content in inactivated LPO
(data not shown); and the ultraviolet-visible
spectral changes observed upon inactivation
of LPO and TPO (33).
Inactivation of TPO by Isoﬂavones
in Vitro
Microsomal rat TPO (rTPO; from
untreated animals) incubated with genistein
and hydrogen peroxide (H2O2) was used to
characterize isoflavone-mediated, time-
dependent TPO inactivation in vitro (35)
(Figure 1). The control experiments demon-
strate that neither H2O2 nor genistein alone
altered activity, consistent with the suicide
inactivation mechanism previously proposed
(33,35) and Scheme 2. The apparent inhibi-
tion binding constant, Ki, and the maximal
inactivation rate constant, kinact, were 50 nM
and 0.28 min-1, respectively. Daidzein like-
wise inactivated TPO, with constants of 143
nM and 0.31 min-1. These kinetic parame-
ters are consistent with very potent inactiva-
tion, unlike other dietary flavonoids tested
(32), and suggest a mechanism for low-dose
effects of soy. The sensitivity of microsomal
rTPO to inactivation by genistein was com-
pared with other mammalian peroxidases
(35). Purified bovine LPO, porcine TPO,
human TPO, and microsomal rTPO all
showed 40–66% inactivation at 30 min,
suggesting that isoﬂavone-mediated inactiva-
tion of TPO is a general phenomenon across
mammalian species.
Dietary Exposure of Sprague-Dawley
Rats to Genistein
The observed isoﬂavone inhibition of perox-
idase activity in vitro led to treatment of
Sprague-Dawley rats with genistein to inves-
tigate possible endocrine disruption in both
dose-range-ﬁnding (36) and multiple-gener-
ation studies (in progress). Genistein doses
of 0, 5, 100, and 500 ppm were adminis-
tered in soy-free basal diet (total genistein
and daidzein ~0.5 ppm each) to pregnant
female rats 4 weeks before mating through
pup weaning at PND 21. This was followed
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Figure 1. Inactivation of rat TPO by genistein in
vitro. Microsomal rTPO was incubated with the
indicated concentrations of genistein in the pres-
ence of H2O2 (100 nM) at room temperature in 0.1
M phosphate buffer, pH 7.0. At various times,
aliquots were removed and remaining activity
determined using a spectrophotometric guaiacol
oxidation assay. 1: control, rTPO alone; 2: control,
rTPO + H2O2; 3: control, rTPO + 1,000 nM genis-
tein. G = concentration of genistein added to TPO
and H2O2. Data from Chang and Doerge (35).Environmental Health Perspectives • VOLUME 110 | SUPPLEMENT 3 | JUNE 2002 351
by consumption of the same diet until
offspring were sacriﬁced at PND 140. Total
blood genistein (i.e., both conjugates and
aglycone) was measured using electrospray
mass spectrometry (ES/MS) (Table 1) (37).
The range of total genistein traversed the
range found in several human populations
(Table 2) (38,39). On the 500 ppm diet, rat
genistein levels were similar to those in
infants on soy formulas (7). Rats on the
100 ppm diet had genistein levels similar to
those found in adults on typical Asian diets
(38) or soy isoflavone dietary supplements
(39). Rats consuming 5 ppm and control
diets had low genistein levels typically found
with a Western diet (Table 1). Female rats
had higher blood genistein levels than males,
consistent with the sex-speciﬁc difference in
genistein elimination half-time (3.0 vs. 4.3
hr in males and females, respectively) (37).
The predominant circulating metabolites
(97–99%) are genistein glucuronides in both
rats (40) and humans (39). The predomi-
nance of circulating metabolites (97–99%) is
consistent with extensive first-pass metabo-
lism of genistein in the gut and/or liver (41).
Intrathyroidal Accumulation 
of Genistein
Both total and aglycone genistein concentra-
tions were measured in thyroids using liquid
chromatography (LC)-ES/MS (35). Figure 2
shows the results for females and males; the
higher average thyroidal levels observed in
females reflected the higher average blood
concentrations. Thyroid genistein aglycone
(i.e., the unconjugated form) was substan-
tially increased relative to that in blood
(18–28% vs. 1–3%). Total thyroidal genis-
tein occurs in the range of 0.1–1.2 nmol/g
tissues and for the aglycone, 0.1–0.3 nmol/g.
Because water accounts for slightly less than
two-thirds of thyroid weight, concentrations
of genistein aglycone were up to 350 nM.
Elevated tissue aglycone levels, up to 100%
of total, were also measured in several male
and female reproductive organs (37). This
demonstrates preferential tissue accumulation
of unconjugated genistein, which is the bio-
logically active form. Intrathyroidal genistein
aglycone levels of 50–300 nM measured in
this study are above concentrations that inac-
tivate rTPO in vitro (Figure 1) (35).
Inactivation of rTPO by Dietary
Genistein in Vivo
Given that the thyroid concentration of
genistein was sufﬁcient to inactivate TPO in
vitro, TPO activity was assayed in rats fed
the genistein-fortified diets. In both male
and female rats, dose-dependent and signiﬁ-
cant decreases in rTPO activity were
observed (Figure 3). Although 80% loss of
rTPO activity was observed in high dose
(500 ppm) females, a dose 100-fold lower (5
ppm) also inactivated signiﬁcant amounts of
rTPO. That suggests that TPO inactivation
can occur, even at very low dietary isoﬂavone
levels. Furthermore, because thyroid genis-
tein concentrations were sufﬁcient to inacti-
vate rTPO in vitro, the reductions seen in
TPO activity could have been due to
enzyme inactivation in vivo.
We found no evidence from LC-ES/MS
analysis of serum or thyroids suggesting min-
imal formation of any of the iodinated genis-
tein species previously characterized in vitro
(33). This finding, coupled with the exten-
sive TPO inactivation in vivo, suggests that
TPO inactivation by covalent binding of
Endocrine Disruptors • Soy estrogenic and goitrogenic activities
Table 1. Genistein consumption and serum levels in Sprague-Dawley rats.
Genistein Estimated 
dose (µg/g  genistein intake Concentration total genistein (µM)c
in diet)a (mg/kg/day)b Males Females 
Basal 0.04 <0.01 <0.01
5 0.4 0.06 ± 0.006 0.10 ± 0.008
100 8 0.59 ± 0.030 0.94 ± 0.21
500 40 6.00 ± 0.65 7.94 ± 2.47
aThe basal soy-free diet, which contained approximately 0.5 ppm total genistein and
daidzein, was fortiﬁed genistein aglycone at the indicated level. bFeed consumption and
body weights were measured for individual animals. cTotal genistein concentration was
measured in serum from male and female rats using LC-ES/MS (limit of quantitation,
0.01 µM).
Table 2. Isoﬂavonea intake and blood concentrations in humans.
Total isoﬂavones  Blood
Population group—soy form (mg/kg/day)b isoﬂavones (µM)
Adults—Western diet Very low Very low
Adults—Asian diet  <1c 0.1–1.2d
Adults—soy nutritional supplement 0.7e 0.5–0.9e
Infants—soy formula 6–9f 2–7f
Adults—soy cancer supplement 200g ?
aTotal active isoflavones = genistein + daidzein. b70 kg body weight. cSoy isoflavone
intake from typical Japanese diet estimated at 30 mg/day (26). dFrom six Japanese
men (37). eFrom three adult volunteers (38). fFrom seven infants (6). gFrom label
instructions. 
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Figure 2. Dietary consumption of genistein
increases intrathyroidal concentrations of genis-
tein. The concentrations of genistein present in
thyroid tissue, both total and aglycone, were
determined using LC-ES/MS for female (A) and
male (B) rats. Statistical significance relative to
the respective control (*) was determined using
Dunnett’s test (p < 0.05). Data represent mean ±
SE (35).
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Figure 3. Dietary consumption of genistein
decreases rat TPO activity. Microsomal rTPO
activity was measured in thyroids from female (A)
and male (B) rats using a spectrophotometric
guaiacol oxidation assay. One-way analysis of
variance demonstrated a significant treatment
effect (p < 0.05) for both males and females, and
statistical significance relative to the respective
control (*) was determined using Dunnett’s test (p
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isoflavones predominates in the rat thyroid
gland over competitive substrate iodination.
This study with genistein appears to be the
first in which chemically induced loss of
TPO activity has been demonstrated both in
vitro and in vivo.
Inactivation of rTPO by Dietary Soy
in Vivo
A diet comparison study was also conducted
in which rats were fed either a standard
rodent diet (NIH 31) containing 5% soy
meal and approximately 60 ppm total
isoflavones or a soy-free basal diet (5K96)
containing approximately 1 ppm total
isoﬂavones (35). In soy, isoﬂavones occur as
various glucoside conjugates (42), so this
study addressed the issue of whether conju-
gation of dietary isoﬂavones produced effects
different from genistein aglycone. TPO
activity was reduced approximately 50% in
male and female rats consuming the stan-
dard soy diet compared with rats fed the
control diet (Figure 4), and the extent of
reduction was consistent with the total
isoflavone blood levels. The average serum
concentrations of total genistein and
daidzein from the NIH 31 diet were 0.35 ±
0.03 and 0.20 ± 0.02 µM, respectively, in
males and 0.62 ± 0.05 and 0.25 ± 0.02 µM,
respectively, in females (43). These results
clearly showed that whether the dietary
isoﬂavone is an aglycone or a glucoside con-
jugate has no effect on total serum iso-
ﬂavones or on TPO inactivation. This result
is consistent with previous studies that
showed administration of genistein aglycone
or conjugates had a minimal effect on the
pharmacokinetics of total isoﬂavone absorp-
tion and elimination in rats, although small
differences in the peak concentrations were
found (44). The isoﬂavone content of typi-
cal open-formula rodent diets can range
from <5 ppm up to 500 ppm (45). These
ﬁndings suggest that additive effects on TPO
activity between soy in rodent diets and
exogenous chemicals being tested for car-
cinogenicity or other toxicities may con-
found the conclusions.
Absence of Hypothyroid Indicators
in Rats Fed Genistein
Given the decreased TPO activity in rats on
genistein-fortified or soy diets, a resultant
hypothyroid state with decreased T3/T4 and
increased TSH levels seemed likely. This was
further reinforced by the known susceptibil-
ity of rats (particularly males) to antithyroid
chemicals (8). However, analysis of T3/T4
and TSH in sera from all rats in both these
studies (35) showed that no treated group
was different from the untreated controls
(data not shown). Consistently, gland
weights and histopathology of thyroid sec-
tions were not different between the control
and 500-ppm genistein groups in a parallel
study (not shown). A recent study showed
no signiﬁcant thyroid histopathology in rats
fed a 20% soy diet (46). These findings
appear paradoxical given the prominent
losses of TPO activity (Figures 3, 4). Unlike
these results, humans consuming soy devel-
oped goiter and elevated TSH, albeit
without changes in T3/T4 (24).
Synergism of Soy with Iodine
Deﬁciency in Producing Hypothyroid
Effects in Rats
The synergism in antithyroid properties of
soy combined with iodine deficiency has
been further elucidated by Ikeda et al. (46).
They showed, as did Kimura et al. (14), that
rats fed an iodine-deficient diet containing
20% defatted soy bean diet developed a
severe hypothyroid state characterized by
decreased T4, increased TSH, increased thy-
roid weight, increased cell proliferation, and
marked histopathological changes.
Histopathology of the anterior pituitary
showed that an unknown component of soy
had a direct action on the pituitary gland.
To further investigate the ability of soy
isoﬂavones to interact with iodine deﬁciency
to produce hypothyroidism, effects on rats
fed soy-free diets (with or without iodine)
were compared with effects on rats fed the
20% defatted soy diet (47). In other groups,
soy isoﬂavones (12–18% genistein aglycone,
12–18% daidzein aglycone, 2–4% glycitein
aglycone) were added to soy-free diets at 0.2
and 0.04%. The 0.04% isoﬂavone diet had
isoflavones at the same level as the 20%
defatted soy diets. As before, the hypothy-
roid state in rats on the 20% defatted soy
diet required iodine deficiency. However,
neither group of isoflavone-supplemented
rats showed hypothyroidism, whether iodine
deficient or iodine replete. These results
suggest that whole soy, but not isoflavones
alone, is required to produce hypo-
thyroidism in iodine-deficient rats. This is
consistent with isoﬂavone inhibition of TPO
synergistically interacting with an unidenti-
fied component(s) of soy to produce
hypothyroidism in iodine-deficient rats.
Additionally, other components of human or
rat diets, or chemical exposures, may cause
goiter in association with soy consumption.
Possible Effects of Soy on Human
Thyroid Health
The total genistein concentrations in rat
serum (Table 1) are similar to those in
humans (Table 2), suggesting a similar tis-
sue exposure. It reasonable to conclude that
human isoflavone consumption could pro-
duce isoflavone levels in the thyroid
(Figure 2) sufficient to inactivate human
TPO, as seen in rats.
The failure to find hypothyroidism
caused by genistein in rats, despite extensive
inactivation of TPO (35), or by mixed
isoﬂavone consumption (47) points to addi-
tional risk factor(s) necessary to induce
hypothyroidism. In particular, iodine defi-
ciency is necessary for soy to cause antithy-
roid effects in rats. Although the mechanism
of this iodide effect is unknown, a signiﬁcant
literature supports this concept (10,14,
46,47). In humans, early findings showed
that goiter in infants fed soy formula was
reversed upon supplementation with iodine
(17). Progression to a hypothyroid state may
also be aided by biochemical impairment of
hormone synthesis and metabolism, and/or
exposure to environmental goitrogens, for
example, sulfonamides, glucosinolates,
cyanogenic glycosides, flavonoids (48), and
persistent halogenated aromatic compounds.
Nonetheless, we should be alert to the ﬁnd-
ing that soy-induced goiter and other
hypothyroid indicators have been reported
in humans in the absence of evidence for
iodine deﬁciency (24).
Soy products are heavily marketed to
postmenopausal women for relief of
menopausal symptoms, despite the absence
of consistent clinical data demonstrating any
such beneﬁt in human trials (25). However,
of concern is that this is the same subgroup
in which frank hypothyroidism and a sub-
clinical hypothyroid state (49) are most
likely to occur (up to 4 and 10%, respec-
tively) (50,51). Further, the incidence of
chronic autoimmune thyroiditis, the major
risk factor for the development of hypothy-
roid disease in women (50), increases with
age in women.
Dietary genistein causes a potent stimula-
tion of T-cell– and B-cell–mediated immu-
nity in rats (36,52), an effect found with
other estrogenic compounds (e.g.,
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Figure 4. Measurement of rTPO activity in rats
consuming either a standard soy-containing
(basal) diet or a soy-free (NIH 31) diet.
Microsomal TPO was isolated from female and
male rats fed NIH 31 diet (~30 ppm each of genis-
tein and daidzein) or the basal diet (~0.5 ppm each
of genistein and daidzein) and rTPO activity
measured spectrophotometrically. Data represent
mean ± SE (35).Environmental Health Perspectives • VOLUME 110 | SUPPLEMENT 3 | JUNE 2002 353
p-nonylphenol, ethinylestradiol). In addition,
suicide inactivation of TPO by dietary genis-
tein in rats likely produces covalent binding
of genistein to TPO. This modiﬁcation could
well be followed by TPO structural changes,
especially in the three-dimensional shape and
charge distribution. This could lead to a new
antigenic form of TPO (a neoantigen) that
could stimulate recognition by the immune
system (53). Further support for this notion
comes from the fact that anti-TPO is the
major thyroid autoantigen circulating in
human serum (54). Although the etiology of
thyroid autoimmunity is unknown, the mul-
titude of genistein effects in rats suggests that
soy consumption could cause or exacerbate
this illness.
Iodine deﬁciency is an emerging concern
in elderly Americans. Consumption of
iodized salt, the primary source of dietary
iodine, may decrease with the desire or need
to reduce the possible hypertensive effects of
high salt intake. The data presented here
suggest that elderly women need to be aware
of, and monitored for, possible thyroid
problems resulting from consumption of soy
products. Those postmenopausal women
who consume large amounts of soy products
may be at higher risk.
Finally, information presented here also
allows a new understanding of the increased
incidence of autoimmune thyroiditis in chil-
dren fed soy formulas reported by Fort et al.
(23). That study has been criticized, and even
dismissed, because children put on soy for-
mula are thought to be more likely to have
autoimmune disorders (e.g., food allergies,
presence of viral gastroenteritis). This assump-
tion, however, can be seriously questioned,
because only 0.5–1.0% of American infants
have true allergies, but about 20% are on soy
formula. The alternative explanation, based on
the findings here, involves stimulation of
immune function by genistein, possible
neoantigen formation through covalent bind-
ing of genistein to TPO, and increasing
autoimmune disease prevalence. This hypoth-
esis provides a plausible explanation for the
observations of Fort et al. (23) and we hope
will encourage further study of autoimmune
thyroiditis in children consuming soy formula.
REFERENCES AND NOTES
1.  Sheehan, DM. Isoﬂavone content of breast milk and soy
formulas: beneﬁts and risks [Editorial]. Clin Chem 43:850
(1997). 
2. Sheehan, DM. Herbal medicines, phytoestrogens, and
toxicity: risk/benefit considerations. Proc Soc Exp Med
Biol 217:379–385 (1998).
3.  Fang H, Tong W, Shi L, Blair R, Perkins R, Branham WS,
Dial SL, Moland CL, Sheehan DM. Structure-activity rela-
tionships for a large diverse set of natural, synthetic and
environmental estrogens. Chem Res Toxicol 14:280–294
(2001).
4.  Medlock KL, Branham WS, Sheehan DM. Effects of
coumestrol and equol on the developing reproductive
tract of the rat. Proc Soc Exp Biol Med 208:67–71
(1995).
5.  Newbold RR, Banks EP, Bullock B, Jefferson WN.
Uterine adenocarcinoma in mice treated neonatally with
genistein. Cancer Res 61:4325–4328 (2001).
6.  Cassidy A, Bingham S, Setchell KDR. Biological effects
of a diet of soy protein rich in isoflavones on the men-
strual cycle of premenopausal women. Am J Clin Nutr
60:333-340 (1994).
7.  Setchell KDR, Zimmer-Nechimias L, Cai J, Heubi JE.
Exposure of infants to phyto-oestrogens from soy-based
infant formula. Lancet 350:23–27 (1997).
8.  Poirier LA, Doerge DR, Gaylor DW, Miller MA, Lorentzen
RJ, Casciano DA, Kadlubar FF, Schwetz BA. An FDA
review of sulfamethazine toxicity. Reg Toxicol
Pharmacol 30:217–222 (1999).
9.  McCarrison R. The goitrogenic action of soybean and
groundnut. Indian J Med Res 21:179–181 (1933).
10.  Block JR, Mand, RH, Howard HW, Bauer CD, and
Anderson DW. The curative action of iodine on soybean
goiter and the changes in the distribution of iodoamino
acids in the serum and in thyroid gland digests. Arch
Biochem Biophys 93:15–24 (1961).
11.  Nordisiek FW. Effects of added casein on goitrogenic
action of different dietary levels of soybeans. Proc Soc
Exp Biol Med 110:417–420 (1962).
12.  Konijn AM, Edelstein S, Guggenheim K. Separation of a
thyroid-active fraction from unheated soya bean flour.
J Sci Food Agric 23:549–555 (1972).
13.  Kay T, Kimura M, Nishing K, Itokawa Y. Soyabean goiter
and prevention. J Trop Pediatr 34:110–113 (1988).
14.  Kimura S, Suwa J, Ito B, Sato H. Development of malig-
nant goiter by defatted soybean with iodine-free diet in
rats. Gann 67:763–765 (1976).
15.  Van Wyk JJ, Arnold MB, Wynn J, and Pepper F. The
effects of a soybean product on thyroid function in
humans. Pediatrics 24:752–760 (1959).
16.  Hydovitz JD. Occurrence of goiter in an infant on a soy-
diet. N Engl J Med 262: 351–353 (1960).
17.  Shepard TH, Pyne GE, Kirschvink JF, McLean CM.
Soybean goiter. N Engl J Med 262:1099–1103 (1960).
18.  Ripp JW. Soybean-induced goiter. Am J Dis Child
102:106–109 (1961).
19.  Pinchera A MacGillivray MH, Crawford JD, and Freeman
AG. Thyroid refractoriness in an athyreotic cretin fed
soybean formula. N Engl J Med 265:83–87 (1965).
20. Labib  M, Gama R, Wright J, Marks V, Robins D. Dietary
maladvice as a cause of hypothyroidism and short
stature. Br Med J 293:232–233 (1989).
21.  Chorazy PA, Himelhoch S, Hopwood NJ, Greger NG,
Postellon DC. Persistent hypothyroidism in an infant
receiving a soy formula: case report and review of the
literature. Pediatrics 96:148–150 (1995).
22.  Jabbar MA, Larrea J, Shaw RA. Abnormal thyroid func-
tion tests in infants with congenital hypothyroidism: the
influence of soy-based formula. J Am Coll Nutr
16:280–282 (1997).
23.  Fort P, Moses N, Fasano M, Goldberg T, Lifshitz F. Breast
and soy-formula feedings in early infancy and the preva-
lence of autoimmune thyroid disease in children. J Am
Coll Nutr 9:164–167 (1990).
24.  Ishizuki Y, Hirooka Y, Murata Y, Togashi K. The effects on
the thyroid gland of soybeans administered experimen-
tally in healthy subjects. Nippon Naibunpi Gakkai Zasshi
67:622–629 (1991).
25.  Duncan AM, Underhill KE, Xu X, Lavalleu J, Phipps WR,
Kurzer MS. Soy isoflavones exert modest hormonal
effects in premenopausal women. J Clin Endocrinol
Metab 84:192–197 (1999).
26.  Watanabe S, Terashima K, Sato Y, Arai S, and Eboshida
A. Effects of isoflavone supplement on healthy women.
BioFactors 12:233–241 (2001).
27.  Doerge DR, Takazawa RS. Mechanism of thyroid peroxi-
dase inhibition by ethylenethiourea. Chem Res Toxicol
3:98–103 (1990).
28.  Doerge DR, Decker CJ. Inhibition of peroxidase-cat-
alyzed reactions by arylamines: mechanism for the anti-
thyroid action of sulfamethazine. Chem Res Toxicol
7:164–169 (1994).
29.  Divi RL, Doerge DR. Mechanism-based inactivation of
lactoperoxidase and thyroid peroxidase by resorcinol
derivatives. Biochemistry 33:9668–9674 (1994).
30.  Doerge DR, Divi RL, Deck J, Taurog A. Mechanism for
the anti-thyroid action of minocycline. Chem Res Toxicol
10:49–58 (1997).
31.  Doerge DR, Chang HC, Divi RL, Churchwell MI.
Mechanism for inhibition of thyroid peroxidase by leuco-
malachite green. Chem Res Toxicol 11:1098–1104 (1998).
32. Divi  RL,  Doerge DR. Inhibition of thyroid peroxidase by
dietary ﬂavonoids. Chem Res Toxicol 9:16–23 (1996).
33. Divi RL, Chang HC, Doerge DR. Anti-thyroid isoflavones
from soybean: isolation, characterization, and mecha-
nisms of action. Biochem Pharmacol 54:1087–1096 (1997).
34.  Taurog A. Thyroid hormone synthesis and secretion. In:
Werner and Ingbar’s The Thyroid (Braverman LE, Utiger
RD, eds). Philadelphia:Lippincott-Raven, 1996;47–84.
35.  Chang HC, Doerge DR. Dietary genistein inactivates rat
thyroid peroxidase in vivo without an apparent hypothy-
roid effect. Toxicol Appl Pharmacol 168:244–252 (2000).
36.  Delclos KB, Bucci TJ, Lomax LG, Latendresse JR,
Warbritton A, Weis CC, Newbold RR . Effects of dietary
genistein exposure during development on male and
female CD (Sprague-Dawley) rats. Reprod Toxicol 15:
647–663 (2001).
37.  Chang HC, Churchwell MI, Delclos KB, Newbold RR,
Doerge DR. Mass spectrometric determination of genis-
tein tissue distribution in diet-exposed Sprague-Dawley
rats. J Nutr 130:1963–1970 (2000).
38.  Adlercreutz H, Fotsis T, Watanabe S, Lampe J, Wahala
K, Makela T, Hase T. Determination of lignans and
isoflavonoids in plasma by isotope dilution gas chro-
matography-mass spectrometry. Cancer Detect Prev
18:259–271 (1994).
39.  Doerge DR, Chang HC, Holder CL, Churchwell MI.
Analysis of soy isoflavone conjugation in vitro and in
human blood using liquid chromatography-mass spec-
trometry. Drug Metab Dispos 28:298–307 (2000).
40.  Holder CL, Churchwell MI, Doerge DR. Quantification of
soy isoﬂavones, genistein and daidzein, and conjugates
in rat blood using LC/ES-MS. J Agric Food Chem
47:3764–3770 (1999).
41.  Sfakianos J, Coward L, Kirk M, Falany CN, Barnes S.
Intestinal uptake and biliary excretion of the isoflavone
genistein in rats. J Nutr 127:126–1268 (1997).
42.  Barnes S, Kirk M. and Coward L. Isoflavones and their
conjugates in soy foods: extraction conditions and analy-
sis by HPLC-mass spectrometry. J Agric Food Chem
42:2466–2474 (1994).
43.  Doerge DR, Churchwell MI, Delclos KB. On-line sample
preparation using restricted-access media in the analysis
of the soy isoﬂavones, genistein and daidzein, in rat seru-
musing liquid chromatography electrospray mass spec-
trometry. Rep Commun Mass Spectrom 14:673–678 (2000).
44.  King RA, Broadbent JL, Head RJ. Absorption and excre-
tion of the soy isoflavone genistein in rats. J Nutr
126:176–182 (1996).
45.  Thigpen JE, Setchell KDR, Ahlmark KB, Locklear J, Spahr
T, Caviness GF, Goelz MF, Haseman JK, Newbold RR,
Forsythe DB. Phytoestrogen content of purified, open-
and closed-formula laboratory animal diets. Lab Anim
Sci 49:530–536 (1999).
46.  Ikeda T, Nishikawa A, Imazawa T, Kimura S, Hirose M.
Dramatic synergism between excess soybean intake and
iodine deficiency on the development of rat thyroid
hyperplasia. Carcinogenesis 21:707–713 (2000).
47.  Son HY, Nishikawa A, Ikeda T, Kimura S, Hirose M. Lack
of effect of soy isoﬂavone on thyroid hyperplasia in rats
receiving an iodine-deficient diet. Jpn J Cancer Res
92:103–108 (2001).
48.  Gaitan E, Lindsay RH, Cooksey RC. Millet and the thyroid.
In: Environmental Goitrogenesis (Gaitan E, ed). Boca
Raton, FL:CRC Press, 1989;195–206.
49.  Woeber KA. Subclinical thyroid dysfunction. Arch Intern
Med 157:1065–1068 (1997).
50.  Vanderpump MPJ, Tunbridge WMG. The epidemiology
of thyroid diseases. In: Werner and Ingbar’s The Thyroid.
(Braverman LE, Utiger RD, eds). Philadelphia:Lippincott-
Raven, 1996;474–482.
51.  Canaris GJ, Manowitz NR, Mayor G, Ridgeway EC. The
Colorado thyroid disease prevalence study. Arch Intern
Med 160:526–534 (2000).
52. Zhang  Y,  Song TT, Cunnick JE, Murphy PA, Hendrich S.
Daidzein and genistein glucuronides in vitro are weakly
estrogenic and activate human natural killer cells at
nutritionally relevant concentrations. J Nutr 129:399–405
(1999).
53. Dansette PM, Bonierbale E, Minoletti C, Beaune PH,
Pessayre D, Mansuy D. Drug-induced immunotoxicity.
Eur J Drug Metab Pharmacokinet 23:443–451 (1998).
54.  McKenzie JM, Zakarija M. Thyroid autoimmunity. In:
Werner and Ingbar’s The Thyroid (Braverman LE, Utiger
RD, eds). Philadelphia:Lippincott-Raven, 1996;416–432.
Endocrine Disruptors • Soy estrogenic and goitrogenic activities